In a pooled data set of clinical trials, the overall incidence of opportunistic infections was 0.09% for the 15,402 subjects who received Enbrel. ###>Selon des données combinées des essais cliniques, l’ incidence globale des infections opportunistes a été de 0,09% chez les 15 402 sujets ayant reçu Enbrel.